| 4:00–8:00 PM | Arrival and Registration | Sweeney Ballroom Foyer |
| 6:00–8:00 PM | Welcome Mixer | Lobby |
| 7:00–8:00 AM | Breakfast | Sweeney F, Main Level Breakouts |
| 7:30–8:00 AM | Poster Setup | Sweeney Ballroom F |
| 8:00–9:30 AM | Welcome and Keynote Session (Joint) | Sweeney Ballroom A-E |
| Tony Wyss-Coray, Stanford University School of Medicine Aging, the Immune System and Neurodegeneration |
| Beth Stevens, Boston Children's Hospital, Harvard Medical School Connecting Human Microglia States to Function in Health and Disease |
| 8:00–7:00 PM | Poster Viewing | Sweeney Ballroom F |
| 9:30–9:50 AM | Coffee Break | Sweeney Ballroom Foyer |
| 9:50–11:15 AM | Immune-CNS Interactions in Neurodegeneration (Joint) | Sweeney Ballroom A-E |
| Christopher K. Glass, University of California, San Diego Transcriptional Regulation of Macrophage Development |
| S. Pablo Sardi, Sanofi Therapeutic Development for Neurodegenerative Disorders |
| Anne Schaefer, Icahn School of Medicine at Mount Sinai, MPI Ageing Epigenetic Regulation of Microglia |
| 11:15–12:15 PM | Lunch | Sweeney F, Main Level Breakouts |
| 11:45–2:30 PM | Poster Session 1 | Sweeney Ballroom F |
| 2:30–4:30 PM | Workshop 1: Immune-CNS Interactions in Neurodegeneration | Sweeney Ballroom A-B |
| Lynn van Olst, Northwestern University Spatial Transcriptomics Reveals Neuroimmune Mechanisms of Aβ Clearance in Immunized Alzheimer’s Disease Patients |
| Georg Werner, Ludwig-Maximilians-Universität München Single Cell Analysis Reveals a Neurodegeneration Specific Microglia Population Resistant to CSF1R Inhibition in a Mouse Model with FTLD-like Pathology |
| Urs Langen, Hoffmann-La Roche AG Beyond the Shuttle: Advances in Brain Delivery of Biologics for the Treatment of Neurodegenerative Diseases |
| Ravi Jagasia, Pharma Research and Early Development Genome-Wide CRISPR-Cas9 Based Screening for Modifiers of Lysosomal GCase Activity Uncovers Candidate Risk Factors for Parkinson Disease |
| Kyle J Travaglini, Allen Institute for Brain Science An Integrated Multimodal Cell Atlas of Alzheimer's Disease |
| Maylin Fu, Stanford University Controlling Endogenous mRNA Localization in the Peripheral and Central Nervous Systems in vivo |
| Philip L. De Jager, Columbia University Medical Center Human Microglia Expressing High Levels of CD74 Expression are Associated with Activation and Cognitive Decline |
| Ian Peikon, Cajal Neuroscience Dire Straits: Loss of Translational Regulation of SNCA by Iron Unifies the Genetics of PD and LBD at the SNCA Locus |
| 4:30–5:00 PM | Coffee Available | Sweeney Ballroom Foyer |
| 5:00–7:00 PM | Neuroimmune Interactions Relevant to NDD | Sweeney Ballroom A-B |
| Kate Monroe, Denali Therapeutics Leveraging Human Genetics for Novel Therapeutic Approaches for Alzheimer's Disease |
| Christian Haass, Ludwig-Maximilians University Munich PGRN/ApoE |
| David M. Holtzman, Washington University Role of APOE in Modulating the Innate and Adaptive Immune Response in Neurodegeneration |
| August Yue Huang, Boston Children's Hospital Short Talk: Short Talk: Alzheimer’s Disease Microglia Exhibit Enriched Proliferation-related Clonal Somatic Mutations Associated with Inflammatory States |
| John D. Fryer, Mayo Clinic Short Talk: Short Talk: Anti-amyloid Immunotherapy Induces Sustained Microglial and Immune Alterations |
| 7:00–8:00 PM | On Own for Dinner |
| 7:00–8:00 AM | Breakfast | Sweeney F, Main Level Breakouts |
| 8:00–11:00 AM | Molecular Mechanisms in NDD | Sweeney Ballroom A-B |
| Soyon Hong, University College London Neuroimmune Signaling Across Gut-Brain Axis Modulates Brain Synucleinopathy |
| Nicholas T. Seyfried, Emory University School of Medicine Integrated Proteomics for Therapeutic Target and Biomarker Discovery in Alzheimer’s Disease |
| Leonard Petrucelli, Mayo Clinic Jacksonville Tmem/PGRN |
| Bakhos Tadros, Baylor College of Medicine Short Talk: Short Talk: LMO7 Modulates Tau Levels by Regulating CHIP-BAG5 Interplay: Novel Insights into Tauopathy Mechanisms |
| Alexi Nott, Imperial College London Short Talk: Short Talk: Vascular–immune Epigenetic Mechanisms Underlying Age-related Brain Disorders |
| Dalya Rosner, Alector Short Talk: Short Talk: The Alzheimer’s Risk Genes MS4A4A and MS4A6A Cooperate to Regulate Key Microglial Functions |
| Roy R. Parker, HHMI/University of Colorado Short Talk: Short Talk: Polyserine Domain RNA-binding Proteins as Cellular Factors Enhancing Tau Aggregation |
| 9:00–9:20 AM | Coffee Break | Sweeney Ballroom Foyer |
| 11:00–1:00 PM | Poster Setup | Sweeney Ballroom F |
| 11:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Sweeney Ballroom F |
| 2:30–4:30 PM | Career Roundtable (Joint) | Sweeney Ballroom D-E |
| Francesca Odoardi, University Medical Center Göttingen Group Leader & Professor |
| Suman Jayadev, University of Washington Associate Professor, Director and Neurogeneticist |
| Arya Biragyn, NIA, National Institutes of Health Senior Investigator |
| Sarah DeVos, Curie.Bio Drug Maker in Residence |
| Tim Spencer, Journal of Cell Biology Executive Editor |
| 4:30–5:00 PM | Coffee Available | Sweeney Ballroom Foyer |
| 5:00–7:00 PM | Susceptibility vs. Resilience: Understanding Region Vulnerability in NDD | Sweeney Ballroom A-B |
| Cagla Eroglu, Duke University Medical Center In vivo Proteomic Tools TurboID |
| Henne Holstege, Amsterdam UMC Cognitively Healthy Centenarians are Genetically Protected Against Alzheimer’s Disease |
| James Gorman, Wyss Institute Targeting Known and Novel Receptors to Deliver Drugs for Neurodegenerative Diseases |
| Guoyan Zhao, Washington University Short Talk: Short Talk: Transcriptomic Changes in Lewy Body Disease and Alzheimer's Disease Linked to Selective Regional and Neuronal Vulnerability |
| Mohammad Abbasi, Arizona State University Short Talk: Short Talk: Unveiling Microglial Heterogeneity in Spatial Context |
| 7:00–8:00 PM | Social Hour with Lite Bites | Sweeney F, Main Level Breakouts |
| 7:30–10:00 PM | Poster Session 2 | Sweeney Ballroom F |
| 7:00–8:00 AM | Breakfast | Sweeney F, Main Level Breakouts |
| 8:00–11:00 AM | Modelling Human NDD in a Dish | Sweeney Ballroom A-B |
| Tarja Malm, University of Eastern Finland Modeling Early Alzheimer’s Disease in Human Context |
| Irene Faravelli, Harvard University Chimeroids as Avatars to Investigate Brain Diseases |
| Martin Kampmann, University of California, San Francisco Elucidating Mechanisms and Therapeutic Targets for Neurodegenerative Diseases by CRISPR-Based Functional Genomics |
| Nilesh Sharma, University of Calgary Short Talk: Short Talk: Metabolic Perturbation in Ependymal Cells Leads to Progressive Peri-ventricular Pathology and Recapitulates Alzheimer’s Disease Pathogenesis |
| Jean Paul Chadarevian, UC Irvine Short Talk: Short Talk: Therapeutic Potential of Human Microglial Transplantation in a Chimeric Model of CSF1R-related Leukoencephalopathy |
| Lulu Jiang, University of Virginia Short Talk: Short Talk: The Innovative Neuron-Glial Brain Assembloid Model of Alzheimer’s Disease Reveals the Differential Role of ApoE Isoforms in Pathological Tau Propagation |
| Mireia Gomez-Budia, University of Eastern Finland Short Talk: Short Talk: Unravelling LTP-like Synaptic Plasticity in Human Cortical Biopsies on Microelectrode Arrays |
| 9:00–9:20 AM | Coffee Break | Sweeney Ballroom Foyer |
| 11:00–1:00 PM | Poster Setup | Sweeney Ballroom F |
| 11:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Sweeney Ballroom F |
| 2:30–4:30 PM | Workshop 2: Steps Toward Precision Medicine for NDD | Sweeney Ballroom A-B |
| Jordan Marks, Mayo Clinic TMEM106B Risk SNP Alters Disease Duration and Fibril Deposition in FTLD-TDP |
| Zhe Zhang, John Hopkins University PTPσ-Mediated PI3P Regulation as a Therapeutic Strategy for C9ORF72-ALS/FTD |
| Tina Schwabe, Nine Square Therapeutics Developing Parkin Activators to Enhance Mitochondrial Function for the Treatment of Parkinson’s Disease |
| Francesca Cignarella, Foundation for the National Institutes of Health (FNIH) Enabling a Precision Medicine Approach to Target and Biomarker Discovery in Alzheimer’s Disease: Accelerating Medicines Partnership® Alzheimer’s Disease (AMP AD) |
| Tong Wu, Washington University in St. Louis Targeting SARM1 Inhibition Provides a Promising Therapeutic Strategy for DNA Damage-Induced Neurodegenerative Diseases, Including Amyotrophic Lateral Sclerosis (ALS) |
| Laura Koenig, Harvard Medical School TYK2 Kinase as a Novel Therapeutic Target in Alzheimer’s Disease |
| Karthik A Raju, Denali Therapeutics GPR34 Loss-of-function Rescues TREM2 Metabolic Dysfunction and Promotes Responsive Microglial States |
| Jing Guo, NICO Therapeutics Decreased Lipidated ApoE-receptor Interactions Confer Protection against Pathogenicity of ApoE and its Lipid Cargoes |
| 4:30–5:00 PM | Coffee Available | Sweeney Ballroom Foyer |
| 5:00–6:45 PM | Designing Better: Steps Toward Precision Medicine for NDD | Sweeney Ballroom A-B |
| Fiona C. Elwood, Janssen R&D Precision Medicine in Neurodegeneration |
| Jia Tay, Prime Medicine, Inc. Prime Editing as a Curative Therapeutic Approach for Neurodegenerative Diseases |
| Bruno Godinho, Atalanta Therapeutics Addressing CNS Indications using a Novel Di-siRNA Modality for Improved Potency, Distribution, and Duration |
| Jeffrey D. Rothstein, Johns Hopkins University ALS and Neurodegeneration Starts at the Nuclear Pore: Insights and Therapy for ALS and Dementia |
| 6:45–7:00 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) | Sweeney Ballroom A-B |
| 7:00–8:00 PM | Social Hour with Lite Bites | Sweeney F, Main Level Breakouts |
| 7:30–10:00 PM | Poster Session 3 | Sweeney Ballroom F |
| 7:00–11:59 PM | Departure |